Literature DB >> 32634576

Human pluripotent stem cells: A toolbox to understand and treat retinal degeneration.

Lise Morizur1, Elise Herardot2, Christelle Monville3, Karim Ben M'Barek4.   

Abstract

Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) are retinal degenerative disorders that dramatically damage the retina. As there is no therapeutic option for the majority of patients, vision is progressively and irremediably lost. Owing to their unlimited renewal and potency to give rise to any cell type of the human adult body, human pluripotent stem cells (hPSCs) have been extensively studied in recent years to develop more physiologically relevant in vitro cellular models. Such models open new perspectives to investigate the pathological molecular mechanisms of AMD and RP but also in drug screening. Moreover, proof-of-concept of hPSC-derived retinal cell therapy in animal models have led to first clinical trials. This review outlines the recent advances in the use of hPSCs in pathological modeling of retinal degeneration and their use in regenerative medicine. We also address the associated limitations and challenges that need to be overcome when using hPSCs.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age-related Macular Degeneration; Cell therapy; Disease modeling; Human pluripotent stem cells; Retinitis Pigmentosa; Retinopathies

Mesh:

Year:  2020        PMID: 32634576     DOI: 10.1016/j.mcn.2020.103523

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  6 in total

1.  Nicotinamide Promotes Formation of Retinal Organoids From Human Pluripotent Stem Cells via Enhanced Neural Cell Fate Commitment.

Authors:  Florian Regent; Zachary Batz; Ryan A Kelley; Linn Gieser; Anand Swaroop; Holly Y Chen; Tiansen Li
Journal:  Front Cell Neurosci       Date:  2022-06-17       Impact factor: 6.147

Review 2.  Human-induced pluripotent stem cells-derived retinal pigmented epithelium, a new horizon for cells-based therapies for age-related macular degeneration.

Authors:  Samaneh Dehghan; Reza Mirshahi; Alireza Shoae-Hassani; Masood Naseripour
Journal:  Stem Cell Res Ther       Date:  2022-05-26       Impact factor: 8.079

3.  Human Stem Cell-Derived Retinal Pigment Epithelial Cells as a Model for Drug Screening and Pre-Clinical Assays Compared to ARPE-19 Cell Line.

Authors:  Carolina Reis Oliveira; Mayara Rodrigues Brandão de Paiva; Marcela Coelho Silva Ribeiro; Gracielle Ferreira Andrade; Juliana Lott Carvalho; Dawidson Assis Gomes; Márcio Nehemy; Sílvia Ligório Fialho; Armando Silva-Cunha; Alfredo Miranda de Góes
Journal:  Int J Stem Cells       Date:  2021-02-28       Impact factor: 2.500

Review 4.  Brain and Retinal Organoids for Disease Modeling: The Importance of In Vitro Blood-Brain and Retinal Barriers Studies.

Authors:  Ilenia Martinelli; Seyed Khosrow Tayebati; Daniele Tomassoni; Giulio Nittari; Proshanta Roy; Francesco Amenta
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

5.  Light-induced charge generation in polymeric nanoparticles restores vision in advanced-stage retinitis pigmentosa rats.

Authors:  S Francia; D Shmal; S Di Marco; E Colombo; F Benfenati; G Chiaravalli; J F Maya-Vetencourt; G Mantero; C Michetti; S Cupini; G Manfredi; M L DiFrancesco; A Rocchi; S Perotto; M Attanasio; R Sacco; S Bisti; M Mete; G Pertile; G Lanzani
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

Review 6.  Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies.

Authors:  Priyalakshmi Panikker; Shomereeta Roy; Anuprita Ghosh; B Poornachandra; Arkasubhra Ghosh
Journal:  Front Med (Lausanne)       Date:  2022-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.